Loading
A phase 2 trial of HG146 in salivary gland cancers and head and neck squamous cell carcinoma, run by HitGen Inc., now recruiting.
Clinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma is a phase 2 interventional study registered as NCT06781567 by HitGen Inc., with 140 participants planned, started 2024-12-13 and due to reach its primary completion in 2028-12-31. Interventions recorded: HG146.
Shares Adenoid cystic carcinoma, Salivary gland cancers and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Salivary gland cancers and the tag pipeline.